Okayama, Japan

Masaharu Murakami


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masaharu Murakami: Innovator in Liposome Technology

Introduction

Masaharu Murakami is a notable inventor based in Okayama, Japan. He has made significant contributions to the field of pharmaceutical technology, particularly in the development of methods to enhance the efficacy of anti-cancer drugs. His innovative approach focuses on reducing the side effects associated with paclitaxel derivatives.

Latest Patents

Murakami holds a patent for a method for producing liposomes that encapsulate paclitaxel monoglycoside and/or docetaxel monoglycoside. This invention aims to improve the introduction efficiency of these paclitaxel derivatives into liposomes, which has historically been a challenge. The method involves bringing a liposome encapsulating a polyoxyethylene ester derivative, a lower alcohol, and a buffer or water into contact with a solution containing the paclitaxel monoglycoside and/or docetaxel monoglycoside dissolved in an alkylene glycol-containing buffer or water. This innovative technique is designed to specifically target cancer cells, thereby enhancing the therapeutic potential of these drugs.

Career Highlights

Throughout his career, Masaharu Murakami has worked with various companies, including Ensuiko Sugar Refining Co., Ltd. and Hiroki Hamada. His experience in these organizations has contributed to his expertise in pharmaceutical innovations and research.

Collaborations

Murakami has collaborated with notable individuals in his field, including Hiroki Hamada and Ichiro Fujiwara. These partnerships have facilitated the advancement of his research and the development of his patented technologies.

Conclusion

Masaharu Murakami's contributions to liposome technology represent a significant advancement in the field of cancer treatment. His innovative methods aim to improve drug delivery systems, ultimately benefiting patients undergoing cancer therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…